Global Targeted Oncology Drugs Market Growth (Status and Outlook) 2025-2031

The global Targeted Oncology Drugs market size is predicted to grow from US$ 128420 million in 2025 to US$ 201430 million in 2031; it is expected to grow at a CAGR of 7.8% from 2025 to 2031.

Targeted Therapies: Personalized cancer treatment drugs are designed to target specific molecules or pathways that play a critical role in the growth and spread of cancer cells. Unlike traditional chemotherapy, which can affect both healthy and cancerous cells, targeted therapies are intended to be more selective, focusing on cancer cells while sparing healthy tissue.

Precision cancer medicine, also known as personalized or targeted cancer therapy, is driven by the growing understanding of cancer"s molecular and genetic complexity. Advances in genomics and biomarker identification have enabled the development of therapies tailored to an individual"s specific cancer characteristics. This approach offers the potential for more effective treatments with fewer side effects compared to traditional chemotherapy. The market benefits from increasing research in oncology, the rise of precision diagnostics, and the growing availability of targeted therapies. However, challenges include the high cost of genetic testing and targeted treatments, as well as the need for comprehensive molecular profiling. Additionally, regulatory approvals and insurance coverage for these therapies can be complex. To maximize the potential of precision cancer medicine, stakeholders must address these challenges, improve accessibility, and continue research into novel biomarkers and therapies to provide tailored cancer care for patients.

LPI (LP Information)' newest research report, the “Targeted Oncology Drugs Industry Forecast” looks at past sales and reviews total world Targeted Oncology Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted Oncology Drugs sales for 2025 through 2031. With Targeted Oncology Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Oncology Drugs industry.

This Insight Report provides a comprehensive analysis of the global Targeted Oncology Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Oncology Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Oncology Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Oncology Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Oncology Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Oncology Drugs market by product type, application, key players and key regions and countries.

Segmentation by Type:
Kinase Inhibitors
Monoclonal Antibodies
PARP Inhibitors
Other

Segmentation by Application:
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine

Please note: The report will take approximately 2 business days to prepare and deliver.